Basel, 06 December 2017 FDA grants Roche’s Avastin full approval for most aggressive form of brain cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted full approval for Avastin® (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy (referred to as... Read more
Download PDF Read more
Basel, 05 December 2017 TECENTRIQ GO29695 (NCT02431208) and BO29562 (NCT02631577) FDA partial clinical hold lifted Roche (SIX: RO, ROG; OTCQX: RHHBY): today announced that following close consultation and agreement on study modifications with the U.S. Food and Drug Administration (FDA), the partial clinical holds placed on the Phase Ib and Phase Ib/II studies evaluating TECENTRIQ... Read more
Basel, 04 December 2017 FDA approves Foundation Medicine’s FoundationOne CDx, the first pan-tumour comprehensive genomic profiling assay incorporating a broad range of companion diagnostics Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved FoundationOne CDx™, Foundation Medicine’s comprehensive companion diagnostic assay for personalised oncology care1. FoundationOne... Read more
A thermal desorption system is a pretreatment unit in which a tube that concentrates volatile components is heated, and the volatile components from the tube are loaded into an analytical instrument with high sensitivity. It has been used for the analysis of toxic substances in the atmosphere and substances responsible for sick house syndrome included... Read more
Download PDF Read more
SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) announced today that the High Court of Justice, Chancery Division, Patents Court in the United Kingdom issued a judgment in its favor in the patent infringement suit filed against Premaitha Health plc, et al. and the patent infringement suit filed against Ariosa Diagnostics, Inc., et al. The Court found... Read more
Basel, 17 November 2017 FDA approves Roche’s Gazyva for previously untreated advanced follicular lymphoma The first treatment option to demonstrate superior progression-free survival over standard-of-care Rituxan-based therapy Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved Gazyva® (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone in... Read more
Basel, 16 November 2017 FDA approves Roche’s Hemlibra (emicizumab-kxwh) for haemophilia A with inhibitors First new medicine in nearly 20 years to treat people with haemophilia A with inhibitors Hemlibra substantially reduced bleeds in adults and children Only medicine that can be self-administered once weekly by injection under the skin (subcutaneously) Roche (SIX: RO, ROG;... Read more
November 14 2017 Shimadzu Scientific Instruments (SSI), the leading provider of cannabis testing instruments, and Northern Michigan University (NMU) announce a collaborative relationship in support of NMU’s new 4-year undergraduate degree program in Medicinal Plant Chemistry. This program is intended to complement the emerging cannabis economy with a specific focus on laboratory analysis, experimental horticulture,... Read more